Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | -1.39% | +13.42% | +184.00% |
08/05 | Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study | CI |
16/04 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+184.00% | 45.74M | |
+30.38% | 684B | |
+29.72% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.49% | 240B | |
+9.60% | 208B | |
-7.24% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- LEXX Stock
- News Lexaria Bioscience Corp.
- Maxim Group Initiates Lexaria Bioscience With Buy Rating, $2 Price Target